Which pharmacy compounds your GLP-1, and why it matters

When you buy compounded semaglutide or tirzepatide through a telehealth program, the program is rarely the place that actually makes the drug. A separate compounding pharmacy does. Which pharmacy, and how it is regulated, is one of the few quality signals you can check before you pay.

503A vs 503B

Compounding pharmacies fall into two categories. A 503A pharmacy is state-licensed and compounds against an individual prescription, one patient at a time. A 503B pharmacy is an FDA-registered outsourcing facility that makes larger batches under federal manufacturing standards (cGMP) and is inspected by the FDA. A 503B facility carries a higher regulatory bar; a reputable 503A is still a legitimate, licensed pharmacy. The label on your medication should trace back to one of these, not to the telehealth brand itself.

What changed in 2026

From 2022 to early 2025, mass compounding of semaglutide and tirzepatide was allowed under an FDA shortage exemption, because both drugs were on the FDA shortage list. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. The wind-down grace period ended around April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. After those dates, compounding a drug that is essentially a copy of an available product lost its shortage-exemption basis. In February 2026 the FDA issued more than 30 warning letters to telehealth platforms and pharmacies, and in April 2026 it proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list. Narrow 503A compounding continues where a prescriber documents a patient-specific clinical need the approved product cannot meet. (FDA clarification, April 2026; FDA 503B proposal, April 2026.)

How to vet your compounding pharmacy

Before you start, it is reasonable to ask any program four questions:

• Is the compounding pharmacy named, and is it a 503A or 503B facility?
• Is it US-licensed, and in which state?
• Does it carry independent accreditation, such as PCAB or NABP?
• Will it provide sterility and potency testing results on request?

A program that names its pharmacy and answers these plainly is giving you more to verify than one that will not.

Who discloses, and who does not

Disclosure is a transparency signal, not a safety verdict. A program that does not publicly name its pharmacy is not necessarily unsafe, but it gives you less to check. Based on each program's own public materials as of June 2026:

Names its pharmacy publicly: Noom Med (acquired its 503A pharmacy, Tailor Made Compounding, outright), Sesame (names Medivant, a 503B facility), Medvi (names Belmar Pharma Solutions), and Lifeforce (names Tailor Made Compounding and GoGoMeds). Mochi Health's partners (Empower and Strive) are identifiable through Eli Lilly litigation filings and patient reports rather than a Mochi disclosure.

Does not publicly name its pharmacy: Henry Meds, Ivim Health, Strut Health, Hone Health, Klarity, Eden, Found and Lindora describe their pharmacies only in general terms (for example "a state-licensed 503A pharmacy" or "a PCAB-accredited partner") without naming them.

Three of these programs received FDA warning letters in February 2026 for misbranding, where the product label implied the telehealth brand was itself the compounder when a third-party pharmacy did the work: Medvi, Ivim and Strut. These are public record.

Bottom line

A named, US-licensed, accredited pharmacy is a stronger signal than a generic description. If a program will not tell you where your medication is made, that is worth weighing alongside the price. Each program page on GLP Chart now shows what we could verify about its compounding pharmacy under "Where it's compounded".